Immatics (NASDAQ:IMTX) Given “Buy” Rating at Chardan Capital

Immatics (NASDAQ:IMTX)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $25.00 target price on the stock. Chardan Capital’s target price would suggest a potential upside of 133.17% from the company’s current price.

IMTX has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a report on Wednesday, October 8th. Guggenheim raised their price objective on shares of Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Zacks Research raised shares of Immatics from a “strong sell” rating to a “hold” rating in a report on Monday, October 13th. Finally, Mizuho raised their price target on Immatics from $19.00 to $23.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.25.

Immatics Trading Up 5.1%

NASDAQ IMTX traded up $0.52 on Monday, hitting $10.72. 85,525 shares of the company traded hands, compared to its average volume of 788,689. The business’s 50 day moving average price is $9.24 and its 200-day moving average price is $6.96. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -10.56 and a beta of 1.24. Immatics has a 52-week low of $3.30 and a 52-week high of $11.25.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Monday, November 17th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.01. The firm had revenue of $6.10 million for the quarter, compared to the consensus estimate of $12.53 million. Immatics had a negative return on equity of 24.16% and a negative net margin of 146.13%. As a group, sell-side analysts predict that Immatics will post -0.72 earnings per share for the current year.

Hedge Funds Weigh In On Immatics

Institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. increased its holdings in Immatics by 38.4% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company’s stock valued at $66,194,000 after acquiring an additional 4,072,226 shares during the last quarter. Baker BROS. Advisors LP grew its position in shares of Immatics by 18.9% during the third quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock valued at $103,042,000 after purchasing an additional 1,925,193 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Immatics in the third quarter worth about $10,181,000. Vestal Point Capital LP lifted its position in shares of Immatics by 14.6% in the first quarter. Vestal Point Capital LP now owns 7,192,700 shares of the company’s stock worth $32,439,000 after buying an additional 917,700 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Immatics by 4,991.1% in the third quarter. Millennium Management LLC now owns 721,866 shares of the company’s stock worth $6,150,000 after buying an additional 707,687 shares in the last quarter. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.